AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
BERKELEY, Calif., March 1 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation today provided an update on key aspects of the development program for TOLAMBA(TM), a ragweed immunotherapeutic.
AAAAI Preview
Dynavax plans to report the positive safety and efficacy data from the company's Phase 2/3 clinical trial of TOLAMBA at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI), Saturday, March 4, 2006, in Miami, Florida.
One key data point in the upcoming presentation is the efficacy result from the interim analysis following the 2004 ragweed season (the first year of the trial). Quintiles, the contract ...
Source: HighBeam Research, Dynavax Provides Update on TOLAMBA Program.